Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.

about

Reclassifying HER2-equivocal disease.

P2860

Q48141313-A3FA7DB5-0072-4768-8898-2DF08D9EE541

P2860

Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.

Item

http://www.wikidata.org/entity/Q48142637

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@en

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@nl

type

Item

label

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@en

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@nl

prefLabel

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@en

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@nl

P1476

Impact of repeat HER2 testing ...... sing 2013 ASCO/CAP guidelines.

@en

P2093

Dan-Yi Lin

http://www.w3.org/2001/XMLSchema#string

Fang-Ping Xu

http://www.w3.org/2001/XMLSchema#string

Hong-Mei Wu

http://www.w3.org/2001/XMLSchema#string

Jie Chen

http://www.w3.org/2001/XMLSchema#string

Jie Xu

http://www.w3.org/2001/XMLSchema#string

Ke-Ping Zhang

http://www.w3.org/2001/XMLSchema#string

Ming-Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao-Xu Long

http://www.w3.org/2001/XMLSchema#string

Xin-Lan Luo

http://www.w3.org/2001/XMLSchema#string

Yi-Fang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The distinctive nature of HER2-positive breast cancers

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.

P2888

s10549-017-4479-y

P304

757-764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4479-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

Kun Wang

Yan-Hui Liu

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28861637

http://www.w3.org/2001/XMLSchema#string

Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.

about

P2860

P2860

Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698